Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.
Share
Why It Matters
An expert analyst became less excited about this company. They lowered their price target from nineteen dollars to fourteen dollars.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.